Company

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson's Disease
AlectorGenentech

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson’s Disease

Alector, Inc. (NASDAQ: ALEC) announced an exclusive global licensing agreement with Genentech, a member of Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), granting Genentech worldwide rights to develop and commercialize…

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene's GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene’s GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaCancer

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

AlectorGlaxoSmithKline

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

ADC / XDCClinical trial approval / initiation

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

HKG: 6622Ophthalmology

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Show More